Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Azelastine - HCl and fluticasone propionate. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Common Drug Review. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that azelastine hydrochloride/ fluticasone propionate (AZE/FP) not be listed for the symptomatic treatment of moderate-to-severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults and adolescents aged 12 years and older for whom monotherapy with either antihistamines or intranasal corticosteroids is not considered sufficient. Indexing Status Subject indexing assigned by CRD MeSH Humans; Rhinitis, Allergic, Seasonal Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32016000169 Date abstract record published 28/01/2016 |